Quince Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 32
- Market Cap
- $29.8M
- Website
- http://quincetx.com
- Introduction
Quince Therapeutics, Inc.(formerly Cortexyme, Inc.） is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline composed of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is...
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Quince Therapeutics presented safety data from its prior Phase 3 ATTeST clinical trial at the 53rd Child Neurology Society Annual Meeting. The study evaluated treatment-emergent adverse events (TEAEs) in Ataxia-Telangiectasia (A-T) patients treated with EryDex for one year. Key findings showed EryDex was generally well-tolerated, with most TEAEs mild to moderate and similar to placebo. Chronic steroid side effects were not observed, and no TEAEs led to death. Three patients were discontinued from the study due to adverse events.
EryDex Shows Promising Safety Data in Phase 3 A-T Trial
Quince Therapeutics presented safety data from its Phase 3 ATTeST trial at the 53rd Child Neurology Society Annual Meeting, showing EryDex was generally well-tolerated with mostly mild to moderate side effects. The company is conducting a pivotal Phase 3 NEAT trial, expecting to enroll 86 patients aged 6-9 years and 20 patients aged 10+ years, with topline results anticipated in Q4 2025 and potential FDA and EMA submissions in 2026.
© Copyright 2024. All Rights Reserved by MedPath